Dr. Shrikant Verma, Ph. D
Dr. Verma is an Assistant Professor in the Department of Personalized and Molecular Medicine, Era University, Lucknow, India. His expertise spans Molecular Biology, Infectious Diseases, Genome Analysis, and Pharmacogenomics, contributing to advancements in Personalized Medicine. With over five years of research experience, he has published 46 articles, reviews, books, and book chapters in reputed journals and academic platforms. In recognition of his impactful work, Dr. Verma was honored with the prestigious Young Scientist Award by the Indian Society of Personalized Medicine. He is also a life member of several prominent scientific societies, underscoring his commitment to collaborative scientific advancement and continuous learning within the biomedical research community. He also serves as Assistant Editor for the International Journal of Molecular Biology and Biochemistry and is a reviewer for the International Journal of Genetics and Genomics. Currently,
RESEARCH, TEACHING, or OTHER INTERESTS
Biochemistry, Genetics and Molecular Biology, Biotechnology, Clinical Biochemistry, Genetics
Precision Medicine in Cardiomyopathy: Advances and Future Directions Mahvish Mehdi, Sushma Verma, Bashir Ahmad Mir, Shrikant Verma, Aliya Abbas Rizvi, Asma Imran Ansari, Mohammad Abbas, Farzana Mahdi Clinical Genetics, 2025 This review explores how precision medicine is transforming the diagnosis, classification, and treatment of cardiomyopathies. It focuses on the integration of genetic profiling, biomarkers, and imaging to deliver more tailored and effective care. We review major cardiomyopathy subtypes: hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular, with a focus on genetic drivers, including mitochondrial mutations. Pediatric forms are discussed in the context of syndromic and non‐syndromic differences. We highlight the clinical value of combining biomarkers (molecular and serological) with imaging modalities, such as echocardiography, for better risk stratification, especially in predicting sudden cardiac death. The utility of animal models in translating genetic findings into disease understanding is also emphasized. Finally, we touch on innovations like genome editing, gene therapies, and pharmacogenomics for personalized treatment. Precision medicine offers a promising future for cardiomyopathy care. By targeting the underlying causes and tailoring treatment to each patient's genetic and molecular profile, we can achieve more accurate diagnoses, better risk prediction, and improved outcomes, bringing us closer to truly individualized cardiovascular care.
Patient Outcomes and Healthcare Practices Before and After COVID-19 Vaccination: A Comprehensive Analysis Asma Imran Ansari, Mohammad Abbas, Aliya Abbas Rizvi, Sheeba Afreen, Shrikant Verma, Mahvish Mehdi, Sushma Verma, Farzana Mahdi Coronaviruses, 2025 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) unleashed a global pneumonia pandemic, causing significant harm to both physical and mental health. It emphasized the urgency for specialized therapies and protective measures. Approaches, including immunotherapy, antiviral drugs, and lifestyle improvements, like diet and exercise, have shown promise in controlling viral spread before widespread vaccination. However, COVID-19 vaccinations, while critical for reducing disease severity, have been associated with potential side effects, including transient cognitive impairment, rare renal disorders, physiologic anomalies, and dermatological reactions. The scientific community continues to rigorously study these issues to ensure the safety and efficacy of vaccination programs and to address the multifaceted impact of the pandemic.
Genetic polymorphisms of IL6 gene –174G > C and –597G > A are associated with the risk of COVID-19 severity Shrikant Verma, Sushma Verma, Faizan Haider Khan, Zeba Siddiqi, Syed Tasleem Raza, Mohammad Abbas, Farzana Mahdi International Journal of Immunogenetics, 2023 Coronavirus disease‐2019 (COVID‐19) is pro‐inflammatory disorder characterized by acute respiratory distress syndrome. Interleukin‐6, a cytokine secreted by macrophages, which mediates an inflammatory response, is frequently increased and associated with the severity in COVID‐19 patients. The differential expression of IL6 cytokine in COVID‐19 patients may be associated with the presence of single nucleotide polymorphisms (SNPs) in regulatory region of cytokine genes. The aim of this study is to investigate the role of two promoter polymorphisms of the IL6 gene (–597G > A and –174G > C) with the severity of COVID‐19. The study included 242 patients, out of which 97 patients with severe symptoms and 145 patients with mild symptoms of COVID‐19. Genotyping of two selected SNPs, rs1800795 (–174G > C) and rs1800797 (–597G > A) of promoter region of IL6 gene, was performed by polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP). In our study, individuals with GC genotypes of IL6 (–174G > C) polymorphism showed significantly higher risk of severity [adjusted odds (OR) 3.86, p <.001] but we did not observe any association of COVID‐19 severity with rs1800797 (–597G > A) polymorphism. The COVID‐19 severity was significantly higher in individuals having ‘C’ allele of IL6 (–174G > C) polymorphism (p = .014). Linkage disequilibrium between rs1800795 (–174G > C) and rs1800797 (–597G > A) showed that individuals having AC* haplotype significantly association with COVID‐19 severity (p = .034). Our results suggest that ‘C’ allele of rs1800795 (–174G > C) polymorphism of IL6 may be the risk allele for severity of COVID‐19 in North Indian population.
Association of GSTM1 and GSTT1 gene polymorphisms with COVID-19 susceptibility and its outcome Mohammad Abbas, Sushma Verma, Shrikant Verma, Sahabjada Siddiqui, Faizan H. Khan, Syed T. Raza, Zeba Siddiqi, Ale Eba, Farzana Mahdi Journal of Medical Virology, 2021 Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has become a global health issue and develops into a broad range of illnesses from asymptomatic to fatal respiratory diseases. SARS‐CoV‐2 infection is associated with oxidative stress that triggers cytokine production, inflammation, and other pathophysiological processes. Glutathione‐S‐transferase (GST) is an important enzyme that catalyzes the conjugation of glutathione (GSH) with electrophiles to protect the cell from oxidative damage and participates in the antioxidant defense mechanism in the lungs. Thus, in this study, we investigated the role of GSTM1 and GSTT1 gene polymorphism with COVID‐19 susceptibility, as well as its outcome. The study included 269 RT‐PCR confirmed COVID‐19 patients with mild (n = 149) and severe (n = 120) conditions. All subjects were genotyped for GSTM1 and GSTT1 by multiplex polymerase chain reaction (mPCR) followed by statistical analysis. The frequency of GSTM1−/−, GSTT1−/− and GSTM1−/−/GSTT1−/− was higher in severe COVID‐19 patients as compared to mild patients but we did not observe a significant association. In the Cox hazard model, death was significantly 2.28‐fold higher in patients with the GSTT1−/− genotype (p = 0.047). In combination, patients having GSTM1+/+ and GSTT1−/− genotypes showed a poor survival rate (p = 0.02). Our results suggested that COVID‐19 patients with the GSTT1−/− genotype showed higher mortality.
Challenges in integration of multiomics in gut microbiome S Verma, S Verma, M Abbas, F Mahdi The Gut Microbiome in Precision Medicine, 189-204 , 2026 2026
Precision Medicine in Cardiomyopathy: Advances and Future Directions M Mehdi, S Verma, BA Mir, S Verma, AA Rizvi, AI Ansari, M Abbas, ... Clinical Genetics 108 (6), 641-653 , 2025 2025 Citations: 1
Association of VDR and TMPRSS2 gene polymorphisms with COVID-19 severity: a computational and clinical study S Verma, S Verma, Z Siddiqi, ST Raza, T Faruqui, AI Ansari, M Abbas, ... Molecular Biology Reports 52 (1), 327 , 2025 2025 Citations: 4
Patient Outcomes and Healthcare Practices Before and After COVID-19 Vaccination: A Comprehensive Analysis AI Ansari, M Abbas, AA Rizvi, S Afreen, S Verma, M Mehdi, S Verma, ... Coronaviruses 6 (2), e060524229709 , 2025 2025
Impact of Socioeconomic Status on COVID-19 Severity among Urban and Rural Areas in India. M Abbas, S Abbas, S Verma, S Afreen, S Verma, F Mahdi Era's Journal of Medical Research 12 (1) , 2025 2025
Targeting the microbiome to improve human health with the approach of personalized medicine: latest aspects and current updates V Shukla, S Singh, S Verma, S Verma, AA Rizvi, M Abbas Clinical Nutrition ESPEN 63, 813-820 , 2024 2024 Citations: 112
Impact of interleukin-1 gene polymorphisms on the severity of COVID-19 S Verma, S Verma, S Afreen, Z Siddiqi, FH Khan, M Abbas, F Mahdi Human Gene 41, 201303 , 2024 2024 Citations: 5
ROLE OF CYTOKINE STORM IN COVID-19 SEVERITY AND ITS TREATMENT MANAGEMENT. S Verma, S Verma, S Afreen, M Abbas, F Mahdi Era's Journal of Medical Research 11 (2) , 2024 2024 Citations: 3
Impact of Type 2 Diabetes Mellitus-Related Factors on Glaucoma: a Comprehensive Review AA Rizvi, M Abbas, AI Ansari, S Verma, S Verma, L Singh, F Mahdi Current Ophthalmology Reports 11 (4), 69-77 , 2023 2023
Dr. Smita Gudadhe BB Kalbande, S Verma 2023
Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach AI Ansari, AA Rizvi, S Verma, M Abbas, Z Siddiqi, D Mishra, S Verma, ... Molecular Genetics and Genomics 298 (4), 803-812 , 2023 2023 Citations: 7
Genetic polymorphisms of IL6 gene–174G> C and–597G> A are associated with the risk of COVID‐19 severity S Verma, S Verma, FH Khan, Z Siddiqi, ST Raza, M Abbas, F Mahdi International journal of immunogenetics 50 (1), 5-11 , 2023 2023 Citations: 28
Trends in Life Science Research Volume I M Singh, P Gugale, S Verma, N Iqbal Medicine 76, 14-20 , 2023 2023
COMBATING THE ANTIMICROBIAL RESISTANCE BY PERSONALIZED MEDICINE: A MINI-REVIEW. S Verma, S Verma, M Abbas, F Mahdi Era's Journal of Medical Research 10 (1) , 2023 2023 Citations: 4
Determinants in tailoring antidiabetic therapies: a personalized approach AA Rizvi, M Abbas, S Verma, S Verma, A Khan, ST Raza, F Mahdi Global Medical Genetics 9 (02), 063-071 , 2022 2022 Citations: 6
Genetic variants and drug efficacy in tuberculosis: a step toward personalized therapy A Khan, M Abbas, S Verma, S Verma, AA Rizvi, F Haider, ST Raza, ... Global medical genetics 9 (02), 090-096 , 2022 2022 Citations: 14
Association of GSTM1 and GSTT1 gene polymorphisms with COVID‐19 susceptibility and its outcome M Abbas, S Verma, S Verma, S Siddiqui, FH Khan, ST Raza, Z Siddiqi, ... Journal of Medical Virology 93 (9), 5446-5451 , 2021 2021 Citations: 53
A perspective of precision medicine in the management of COVID-19 S Verma, M Abbas, S Verma, AA Rizvi, A Khan, S Tasleem Novel Research in Microbiology Journal 5 (4), 1313-1324 , 2021 2021 Citations: 1
RISK OF MUCORMYCOSIS IN COVID-19 PATIENTS: A REVIEW S Verma, M Abbas, S Verma, AA Rizvi, A Khan, ST Raza, F Mahdi Era's Journal of Medical Research 8 (2), 199-203 , 2021 2021
Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients S Verma, M Abbas, S Verma, FH Khan, ST Raza, Z Siddiqi, I Ahmad, ... Infection, Genetics and Evolution 91, 104801 , 2021 2021 Citations: 98
MOST CITED SCHOLAR PUBLICATIONS
Targeting the microbiome to improve human health with the approach of personalized medicine: latest aspects and current updates V Shukla, S Singh, S Verma, S Verma, AA Rizvi, M Abbas Clinical Nutrition ESPEN 63, 813-820 , 2024 2024 Citations: 112
Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients S Verma, M Abbas, S Verma, FH Khan, ST Raza, Z Siddiqi, I Ahmad, ... Infection, Genetics and Evolution 91, 104801 , 2021 2021 Citations: 98
Association of GSTM1 and GSTT1 gene polymorphisms with COVID‐19 susceptibility and its outcome M Abbas, S Verma, S Verma, S Siddiqui, FH Khan, ST Raza, Z Siddiqi, ... Journal of Medical Virology 93 (9), 5446-5451 , 2021 2021 Citations: 53
Genetic polymorphisms of IL6 gene–174G> C and–597G> A are associated with the risk of COVID‐19 severity S Verma, S Verma, FH Khan, Z Siddiqi, ST Raza, M Abbas, F Mahdi International journal of immunogenetics 50 (1), 5-11 , 2023 2023 Citations: 28
Genetic variants and drug efficacy in tuberculosis: a step toward personalized therapy A Khan, M Abbas, S Verma, S Verma, AA Rizvi, F Haider, ST Raza, ... Global medical genetics 9 (02), 090-096 , 2022 2022 Citations: 14
Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach AI Ansari, AA Rizvi, S Verma, M Abbas, Z Siddiqi, D Mishra, S Verma, ... Molecular Genetics and Genomics 298 (4), 803-812 , 2023 2023 Citations: 7
Determinants in tailoring antidiabetic therapies: a personalized approach AA Rizvi, M Abbas, S Verma, S Verma, A Khan, ST Raza, F Mahdi Global Medical Genetics 9 (02), 063-071 , 2022 2022 Citations: 6
Impact of interleukin-1 gene polymorphisms on the severity of COVID-19 S Verma, S Verma, S Afreen, Z Siddiqi, FH Khan, M Abbas, F Mahdi Human Gene 41, 201303 , 2024 2024 Citations: 5
Association of VDR and TMPRSS2 gene polymorphisms with COVID-19 severity: a computational and clinical study S Verma, S Verma, Z Siddiqi, ST Raza, T Faruqui, AI Ansari, M Abbas, ... Molecular Biology Reports 52 (1), 327 , 2025 2025 Citations: 4
COMBATING THE ANTIMICROBIAL RESISTANCE BY PERSONALIZED MEDICINE: A MINI-REVIEW. S Verma, S Verma, M Abbas, F Mahdi Era's Journal of Medical Research 10 (1) , 2023 2023 Citations: 4
ROLE OF CYTOKINE STORM IN COVID-19 SEVERITY AND ITS TREATMENT MANAGEMENT. S Verma, S Verma, S Afreen, M Abbas, F Mahdi Era's Journal of Medical Research 11 (2) , 2024 2024 Citations: 3
Effectiveness of Blood Pressure and Body Temperature Screening for Severity in COVID-19 Patients S Verma, M Abbas, S Verma, A Khan, AA Rızvı, F Mahdı Journal of Microbiology and Infectious Diseases 11 (03), 147-151 , 2021 2021 Citations: 3
Precision Medicine in Cardiomyopathy: Advances and Future Directions M Mehdi, S Verma, BA Mir, S Verma, AA Rizvi, AI Ansari, M Abbas, ... Clinical Genetics 108 (6), 641-653 , 2025 2025 Citations: 1
A perspective of precision medicine in the management of COVID-19 S Verma, M Abbas, S Verma, AA Rizvi, A Khan, S Tasleem Novel Research in Microbiology Journal 5 (4), 1313-1324 , 2021 2021 Citations: 1
Challenges in integration of multiomics in gut microbiome S Verma, S Verma, M Abbas, F Mahdi The Gut Microbiome in Precision Medicine, 189-204 , 2026 2026
Patient Outcomes and Healthcare Practices Before and After COVID-19 Vaccination: A Comprehensive Analysis AI Ansari, M Abbas, AA Rizvi, S Afreen, S Verma, M Mehdi, S Verma, ... Coronaviruses 6 (2), e060524229709 , 2025 2025
Impact of Socioeconomic Status on COVID-19 Severity among Urban and Rural Areas in India. M Abbas, S Abbas, S Verma, S Afreen, S Verma, F Mahdi Era's Journal of Medical Research 12 (1) , 2025 2025
Impact of Type 2 Diabetes Mellitus-Related Factors on Glaucoma: a Comprehensive Review AA Rizvi, M Abbas, AI Ansari, S Verma, S Verma, L Singh, F Mahdi Current Ophthalmology Reports 11 (4), 69-77 , 2023 2023
Dr. Smita Gudadhe BB Kalbande, S Verma 2023
Trends in Life Science Research Volume I M Singh, P Gugale, S Verma, N Iqbal Medicine 76, 14-20 , 2023 2023
